Document is current
Any future updates will be listed below
-
Authors
Singh, Richa https://orcid.org/0000-0002-3730-496X
Venkadakrishnan, Varadha Balaji https://orcid.org/0000-0001-7071-4584
Imada, Eddie
Yamada, Yasutaka
Brady, Nicholas J. https://orcid.org/0000-0002-2928-0232
Dunmore, Kate E. https://orcid.org/0009-0003-9935-2830
Garner, Richard
Booker, Matthew A.
Hanratty, Brian https://orcid.org/0000-0003-4580-649X
Haffner, Michael C.
Tolstorukov, Michael Y. https://orcid.org/0000-0002-9134-8808
Marchionni, Luigi https://orcid.org/0000-0002-7336-8071
Robinson, Brian D. https://orcid.org/0000-0001-5374-890X
Rickman, David S. https://orcid.org/0000-0001-7420-5883
Beltran, Himisha https://orcid.org/0000-0003-3259-2226
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA241486-01A1)
U.S. Department of Defense (W81XWH2210197)
Prostate Cancer Foundation (23YOUNG15)
National Cancer Center
- License Information
-
More Information
Article History
Received: 22 July 2025
Accepted: 28 January 2026
First Online: 21 February 2026
Competing interests
: D.S.R. has received research funding (to institution) from Janssen, Eli Lilly and Chimerix. M.C.H. served as a paid consultant/received honoraria from Pfizer and Astra Zeneca and has received research funding from Merck, Novartis, Genentech, Promicell and Bristol Myers Squibb. H.B. has served as consultant/advisory board member for Janssen, Astra Zeneca, Merck, Pfizer, Amgen, Bayer, Novartis, Daiichi Sankyo, Abbvie, and has received research funding (to institution) from Janssen, Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo, Novartis, Abbvie. All other authors declare no potential conflicts of interest.
